★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★Open research. Global perspectives.
editor@theamericanjournals.comPublisher Home ↗
Medical Science OPEN ACCESS

Effect of A Modified Ketogenic Diet on The Hepatobiliary System in Experimental Metabolic Syndrome: Dynamics of Apolipoprotein E and Lipoprotein Lipase

Alimov S.M.
Tashkent State Medical University, Tashkent, Uzbekistan
Tursunov D.Kh.
Tashkent State Medical University, Tashkent, Uzbekistan
DOI Crossref DOI 10.37547/tajmspr/Volume08Issue05-25
tajmspr 2026
VOL. 8 / NO. 05 MAY
FULL TEXT PP. 139-143
DOWNLOAD PDF

View all articles in this issue ↗

VOLUME 8
ISSUE 05
YEAR 2026
PAGES 139-143
RESEARCH OVERVIEW

Abstract

Background: Metabolic syndrome (MetS) is accompanied by dyslipidemia, impaired glucose homeostasis, systemic inflammation, and hepatobiliary dysfunction [1, 2]. Apolipoprotein E (ApoE) and lipoprotein lipase (LPL) are key components of triglyceride-rich lipoprotein metabolism [7–9]. Objective: To evaluate the effects of a modified ketogenic diet (MKD; 60% fat, 30% protein, 10% carbohydrate) on hepatobiliary, metabolic, inflammatory, and lipoprotein-related parameters in an experimental rabbit model of MetS, with particular emphasis on ApoE and LPL dynamics. Methods: Sixty Chinchilla rabbits entered the experiment. Eight formed the intact control group, whereas MetS was induced in 52 animals for 60 days using crystalline cholesterol (250 mg/kg), 5% sucrose solution, and subcutaneous insulin (0.1 U/100 g every other day) [5]. Four animals died during induction. The remaining 48 animals with MetS were allocated to six groups (n=8 each): MetS control, traditional ketogenic diet (TKD), MKD, MKD+ezetimibe (0.14 mg/kg/day), MKD+metformin (25 mg/kg/day), and MKD+metformin+ezetimibe. Treatment lasted 30 days. Biochemical variables were assessed on days 10, 20, and 30; ApoE and LPL were measured by ELISA. Results: In the MKD group, ALT decreased from 64.4±5.8 U/L on day 10 to 49.9±4.8 U/L on day 30, GGT from 14.9±1.6 to 12.4±1.2 U/L, and albumin increased from 35.9±3.2 to 40.5±3.9 g/L. ApoE decreased from 26.2±1.2 to 23.2±1.2 and 21.2±1.1 mg/dL, whereas LPL increased from 25.8±0.8 to 27.0±0.8 and 30.8±0.9 ng/mL on days 10, 20, and 30, respectively. Conclusion: MKD was associated with improvement in hepatobiliary, metabolic, inflammatory, and lipoprotein-related indices in experimental MetS. ApoE and LPL showed clear time-dependent responses and warrant further investigation as research indicators of lipoprotein metabolic changes.

RESEARCH TOPICS

Keywords

Metabolic syndrome modified ketogenic diet lipoprotein lipase

Downloads

Download data is not yet available.
SOURCES & SCHOLARSHIP

References

  1. Saklayen M.G. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. doi:10.1007/s11906-018-0812-z.
  2. Alberti K.G.M., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644.
  3. Ministry of Health of the Republic of Uzbekistan. National clinical guideline for the diagnosis and treatment of metabolic syndrome. Tashkent; 2022. [In Uzbek].
  4. Rinella M.E., Lazarus J.V., Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986.
  5. Saidov S.A. Experimental model of metabolic syndrome and its biochemical characteristics. Bulletin of the Tashkent Medical Academy. 2006;(2):45–49. [In Uzbek].
  6. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–861. doi:10.1016/S2468-1253[22]00165-0.
  7. Mahley R.W. Apolipoprotein E: remarkable protein sheds light on cardiovascular and neurological diseases. Clin Chem. 2016;62(11):1401–1411. doi:10.1373/clinchem.2016.255760.
  8. Mahley R.W., Huang Y., Rall S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). J Lipid Res. 1999;40(11):1933–1949.
  9. Mead J.R., Irvine S.A., Ramji D.P. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002;80(12):753–769. doi:10.1007/s00109-002-0384-9.
  10. Sun K., Li W., Chen Y. et al. Ketogenic diets and metabolic dysfunction-associated steatotic liver disease: a literature review. Cell Biosci. 2026;16(1):5. doi:10.1186/s13578-025-01494-8.
  11. EASL–EASD–EASO. Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542. doi:10.1016/j.jhep.2024.04.031.
  12. Tendler D., Lin S., Yancy W.S. Jr. et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci. 2007;52(2):589–593. doi:10.1007/s10620-006-9433-5.
  13. Browning J.D., Baker J.A., Rogers T. et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr. 2011;93(5):1048–1052. doi:10.3945/ajcn.110.007674.
  14. Festi D., Colecchia A., Orsini M. et al. Gallbladder motility and gallstone formation in obese patients following very low calorie diets. Int J Obes Relat Metab Disord. 1998;22(6):592–600. doi:10.1038/sj.ijo.0800634.
  15. Foretz M., Guigas B., Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569–589. doi:10.1038/s41574-019-0242-2.
  16. Altmann S.W., Davis H.R. Jr., Zhu L.J. et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–1204. doi:10.1126/science.1093131.
  17. Basciano H., Federico L., Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond). 2005;2:5. doi:10.1186/1743-7075-2-5.
  18. Volpe C.M.O., Villar-Delfino P.H., dos Anjos P.M.F., Nogueira-Machado J.A. Cellular death, reactive oxygen species and diabetic complications. Cell Death Dis. 2018;9:119. doi:10.1038/s41419-017-0135-z.
  19. Li J., Xie S., Teng W. Sulforaphane attenuates nonalcoholic fatty liver disease by inhibiting hepatic steatosis and apoptosis. Nutrients. 2022;14(1):76. doi:10.3390/nu14010076.
  20. Calder P.C. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105–1115. doi:10.1042/BST20160474.
  21. Youm Y.H., Nguyen K.Y., Grant R.W. et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263–269. doi:10.1038/nm.3804.
  22. European Association for the Study of the Liver (EASL), EASD, EASO. Clinical Practice Guidelines on the Management of MASLD. Obes Facts. 2024;17(4):374–444. doi:10.1159/000539371.
  23. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–923. doi:10.1053/jhep.2003.50161.
  24. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428. doi:10.1016/S0140-6736[05]66378-7.
  25. Stern U.M., Wagenpfeil G., Weber S.N. et al. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomized controlled trials. Eur J Nutr. 2026;65(2):58. doi:10.1007/s00394-025-03870-z.